The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Open accessAbstract
BACKGROUND: Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve implantation (TAVI) has been suggested as a less invasive treatment for high-risk patients with aortic stenosis. METHODS: We randomly assigned patients with severe aortic stenosis, whom surgeons considered not to be suitable candidates for surgery, to standard therapy (including balloon aortic valvuloplasty) or transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve. The primary end point was the rate of death from any cause. RESULTS: A total of 358 patients with aortic stenosis who were not considered to be suitable candidates for surgery underwent randomization at 21 centers (17 in the United States). At 1 year, the rate of death from any cause (Kaplan–Meier analysis) was 30.7% with TAVI, as compared with 50.7% with standard therapy (hazard ratio with TAVI, 0.55; 95% confidence interval [CI], 0.40 to 0.74; P<0.001). The rate of the composite end point of death from any cause or repeat hospitalization was 42.5% with TAVI as compared with 71.6% with standard therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; P<0.001). Among survivors at 1 year, the rate of cardiac symptoms (New York Heart Association class III or IV) was lower among patients who had undergone TAVI than among those who had received standard therapy (25.2% vs. 58.0%, P<0.001). At 30 days, TAVI, as compared with standard therapy, was associated with a higher incidence of major strokes (5.0% vs. 1.1%, P=0.06) and major vascular complications (16.2% vs. 1.1%, P<0.001). In the year after TAVI, there was no deterioration in the functioning of the bioprosthetic valve, as assessed by evidence of stenosis or regurgitation on an echocardiogram. CONCLUSIONS: In patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI, as compared with standard therapy, significantly reduced the rates of death from any cause, the composite end point of death from any cause or repeat hospitalization, and cardiac symptoms, despite the higher incidence of major strokes and major vascular events. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients at high or prohibitive risk of operative mortality, with surgical AVR, TAVR has been a transformative innovation, providing a life-saving treatment for patients who were previously not candidates for AVR”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Balloon-expandable and self-expanding transcatheter valves have been the most rigorously studied to date, specifically the CoreValve (Medtronic, Dublin, Ireland) and SAPIEN (Edwards, Irvine CA, USA) valves”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although, in general, TAVR is associated with a survival advantage compared to conservative (no AVR) management”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“among inoperable patients treated with TAVR in the PARTNER I Cohort B trial (Table 4), at 1 year after the procedure approximately 31% were dead and 18 % had less than a moderate improvement in their quality of life or New York Heart Association functional class201;244”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is a sizable sub-group that dies soon after TAVR or does not experience an improvement in quality of life, suggesting potential futility of TAVR in some patients201;202;220;244;245.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of considerable coronary disease in the setting of severe AS increases with age and was as high as 75% in recent trials comprised mostly of very elderly patients201;220.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are at high-risk for surgical interventions were previously not treated with AVR, TAVR has been a transformative innovation that has improved survival and quality of life200;201.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with inoperable patients treated with conservative management, patients treated with TAVR had less severe heart failure symptoms and better disease-specific and generic health status over the year after randomization201;244.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, older (> 80 years) and sicker patients who previously were not candidates for definitive therapy are being treated200;201.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
The cited source says what the claim attributes to it.
In the citing paper
“In the PARTNER Trial, there was a 20% absolute reduction in 1-year mortality (HR 0.55; 95% CI 0.40 to 0.74) with TAVR compared to standard therapy (30.7% versus 50.7%)201.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
The cited source says what the claim attributes to it.
In the citing paper
“This survival benefit was accompanied by relief of symptoms and improvement in functional capacity in many patients201;225.”
From Calcific aortic stenosis (2016) · cites this paper as [201]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Clinical End Points in Coronary Stent Trials
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A. B., Cohen, D. J., van Es, G., Steg, P. G., Morel, M., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,501
Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis
Cribier, A. G., Eltchaninoff, H., Bash, A., Borenstein, N., Tron, C., Bauer, F., Dérumeaux, G., Anselme, F., Laborde, F., & Leon, M. B. (2002) · Circulation · doi:10.1161/01.cir.0000047200.36165.b8 · Cited by 3,169
Self-citationThe Society of Thoracic Surgeons 2008 Cardiac Surgery Risk Models: Part 2—Isolated Valve Surgery
O’Brien, S. M., Shahian, D. M., Filardo, G., Ferraris, V. A., Haan, C. K., Rich, J. B., Normand, S. T., DeLong, E. R., Shewan, C. M., Dokholyan, R. S., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.05.056 · Cited by 1,259
Shahian, D. M., O’Brien, S. M., Filardo, G., Ferraris, V. A., Haan, C. K., Rich, J. B., Normand, S. T., DeLong, E. R., Shewan, C. M., Dokholyan, R. S., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.05.053 · Cited by 1,256
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.190748 · Cited by 1,128
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?
Iung, B., Cachier, A., Baron, G., Messika-Zeitoun, D., Delahaye, F., Tornos, P., Gohlke-Bärwolf, C., Boersma, E., Ravaud, P., & Vahanian, A. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi471 · Cited by 1,108
Rodés‐Cabau, J., Webb, J. G., Cheung, A. W., Ye, J., Dumont, É., Feindel, C. M., Osten, M., Natarajan, M. K., Velianou, J. L., Martucci, G. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.014 · Cited by 970
Self-citationPercutaneous Aortic Valve Implantation Retrograde From the Femoral Artery
Webb, J. G., Chandavimol, M., Thompson, C., Ricci, D. R., Carere, R. G., Munt, B. I., Buller, C. E. H., Pasupati, S., & Lichtenstein, S. V. (2006) · Circulation · doi:10.1161/circulationaha.105.582882 · Cited by 897
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Murphy ES, 1981, Circulation, 64, II
- 10.1016/j.athoracsur.2009.05.056 · DOI
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Smith, C. R., Leon, M. B., Mack, M. J., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103510 · Cited by 6,345
Self-citation
Metadata
- Authors
- Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., Brown, D. L., Block, P. C., Guyton, R. A., Pichard, A. D., Bavaria, J. E., Herrmann, H. C., Douglas, P. S., Petersen, J. L., Akin, J. J., Anderson, W. N., Wang, D., & Pocock, S.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Medical City Dallas Hospital (US)
- Stanford Medicine (US)
- Cleveland Clinic (US)
- University of British Columbia (CA)
- Cedars-Sinai Medical Center (US)
- Emory University (US)
- MedStar Washington Hospital Center (US)
- Hospital of the University of Pennsylvania (US)
- Duke Medical Center (US)
- Edwards Lifesciences (United States) (US)
- London School of Hygiene & Tropical Medicine (GB)
- ORCID
- Leon, Martin B.
- Smith, Craig R.
- Mack, Michael
- Miller, D. Craig
- Moses, Jeffrey W.
- Svensson, Lars G.
- Tuzcu, E. Murat
- Webb, John G.
- Fontana, Gregory P.
- Makkar, Raj R.
- Brown, David L.
- Block, Peter C.
- Guyton, Robert A.
- Bavaria, Joseph E.
- Herrmann, Howard C.
- Douglas, Pamela S.
- Anderson, William N.
- Wang, Duolao
- Pocock, Stuart
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-21
- Volume
- 363
- Issue
- 17
- Pages
- 1597-1607
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149609916
- Cited by
- 7,205
- References
- 43
- Citations by year
- 2026: 226 · 2025: 309 · 2024: 312 · 2023: 349 · 2022: 374 · 2021: 410 · 2020: 462 · 2019: 521 · 2018: 503 · 2017: 565 · 2016: 555 · 2015: 570 · 2014: 511 · 2013: 580 · 2012: 569
- FWCI
- 335.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- transcatheter aortic valve implantation, severe aortic stenosis, inoperable patients, bovine pericardial valve, transfemoral access, balloon aortic valvuloplasty, all-cause mortality, stroke, vascular complications, cardiac symptoms, high-risk surgical patients, bioprosthetic valve durability, recurrent hospitalization
- MeSH terms
- Aged, Aged, 80 and over, Aortic Valve Stenosis, Cardiovascular Diseases, Catheterization, Echocardiography, Female, Cardiac Catheterization, Hospitalization, Humans, Male, Prospective Studies, Treatment Outcome, Heart Valve Prosthesis Implantation, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
